Swiss drug developer Windward Bio Group AG is targeting a valuation of up to $1 billion in its US initial public offering, according to Reuters. The company is seeking to raise up to $185.3 million by selling roughly 10.3 million shares priced between $16 and $18, it said on Monday.
Basel-based Windward is developing antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease and atopic dermatitis. The company has raised $310 million in equity financing from Novo Holdings and other healthcare investors, including OrbiMed, Blue Owl and RTW Investments.
French drugmaker Sanofi has agreed to buy $50 million of shares and pre-funded warrants in a private placement. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are underwriting the offering. Windward will list on the Nasdaq under the symbol "WWB."
The report says the healthcare industry has anchored the fall IPO window this year as choppy market conditions and rising borrowing costs weigh on other sectors. Drug developer Rezera also began its US IPO roadshow last week and is expected to go public in New York this week.